



BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015.

Tel. : 0731-2723016 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com

Factory : Plot No. 8, Sector - III, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.) PIN - 454 775

Date: 13th August 2021

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-2426700, 2426718 • **CIN:** L24233MP1985PLC002709

To,
The Company Secretary,
Corporate Compliance Department
The National Stock Exchange of India
Limited
Bandra Kurla Complex, Mumbai

To,
The Company Secretary
Corporate Compliance Department
BSE Limited
Dalal Street, P.J. Tower, Mumbai

Sub: - Outcome of the Board Meeting held on Friday, 13th August 2021 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref- Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN INE829A01014)

Dear Sir/Madam,

With reference to the above-mentioned subject and as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of the Directors of the Company in their meeting (No. 03/2021-22) held on today i.e. Friday 13th day of August 2021, following matters have been inter alia transacted along with other routine businesses:-

1. Approval of the Un-Audited Financial Result and Limited Review Report thereon for the Quarter ended on 30th June, 2021. Copy of Un-Audited Financial statements for quarter 30th June, 2021 being submitted separately.
2. Approval of Boards' Report on the operation of the Company & its Annexure along with Corporate Governance Report & Management Discussion and Analysis Report for the year ended on 31st March 2021
3. Approval of notice of 36th Annual General Meeting to be held on Monday, 27th September 2021 through Video Conferencing (VC)/ Other Audio Visual Means.
4. Fixation of date of closure of Register of Members and Share Transfer Book of the Company i.e. from Tuesday, 21st Day of September, 2021 to Monday, 27th Day of September, 2021 (both days inclusive) for the purpose of 36th Annual General Meeting.
5. Fixation of cut-off date i.e. Monday, 20th September, 2021 for the purpose of members eligible for Remote E-voting and voting at the time of 36th Annual General Meeting.
6. Appointment of Mr. L.N. Joshi as Scrutinizer for the process of Remote E-Voting as well as voting at the 36th Annual General Meeting (Insta Poll).
7. Re-appointment of M/s L.N. Joshi and Company, Practicing Company Secretaries as Secretarial Auditors of the Company for the Financial Year 2021-22.

Further, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to the Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is filed separately.

The meeting of the Board of Directors commenced at 4.00 p.m. and concluded at 5.45 p.m.

This is for your information and record.

Thanking You,

Yours faithfully

For Biofil Chemicals and Pharmaceuticals Limited



Shikha Khilwani

Company Secretary & Compliance Officer

ACS 43203



BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015.

Tel. : 0731-2723016 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com

Factory : Plot No. 8, Sector - III, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.) PIN - 454 775

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-2426700, 2426718 • CIN : L24233MP1985PLC002709

Date: 13th August 2021

To,
The Company Secretary,
Corporate Compliance Department
The National Stock Exchange of India
Limited
Bandra Kurla Complex, Mumbai

To,
The Company Secretary
Corporate Compliance Department
BSE Limited
Dalal Street, P.J. Tower, Mumbai 400001

Sub: Submission of Un-Audited Financial Result of the Company for the quarter ended on 30th June, 2021 and Limited Review Report as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref- Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN INE829A01014)

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are hereby enclosing Un-Audited Financial Results together with Limited Review Report thereon for the quarter 30th June 2021 duly approved by the Board of Directors of the Company at its meeting held today i.e. on Friday, 13th August 2021 at the Registered office of the Company. **Copy of Unaudited Financial Results along with Limited Review Report is enclosed with this letter (searchable PDF mode).**

Further, copy of Un-Audited Financial Statements shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. The Results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net.

You are requested to take on record the above said financial results for your reference and record.

Thanking You,

Yours faithfully

For Biofil Chemicals and Pharmaceuticals Limited


Shikha Khilwani

Company Secretary & Compliance Officer

ACS 43203

Encl: a/a


Biofil Chemicals & Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com, Website: https://www.biofilgroup.net/ Phone No. 0731-2426718

Statement of Unaudited Financial Results for the quarter ended 30th June 2021 (Amount in Lakhs except EPS)

	Particulars	3 Month Ended 30/06/2021	3 Month Ended 30/06/2020	3 Month Ended 31/03/2021	Previous year ended on March 31 2021
		Un Audited	Un Audited	Audited	Audited
I	Revenue from Operation				
II	Other Income	536.87	230.11	1423.87	3,575.04
		2.06	63.62	-0.43	79.99
III	Total Income (I + II)	538.94	293.72	1423.44	3655.04
IV	Expenses				
	(a) Cost of materials consumed				
	(b) Purchases of stock-in-trade	55.85	139.65	130.33	685.12
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	47.36	1209.89	1546.90	2834.43
	(d) Employee benefits expense	363.63	(1122.16)	(335.19)	(276.86)
	(e) Finance Cost	17.41	16.75	11.50	75.16
	(f) Depreciation and Amortisation Expense	0.97	2.45	(8.51)	6.81
	(g) Other expenses	10.30	10.21	18.93	41.19
	Total expenses (IV)	19.32	15.27	33.20	97.29
V	Profit/ (Loss) before exceptional items and tax (III-IV)	514.84	272.06	1397.18	3463.14
VI	Exceptional Items	24.09	21.66	26.27	191.89
VII	Profit/ (Loss) before tax (V - VI)	0.00	0.00	0.00	0.00
VIII	Tax expense:	24.09	21.66	26.27	191.89
	(1) Current tax	6.70	0.00	32.75	32.75
	(2) Deferred tax Credit/(Charge)	0.00	0.00	35.01	35.01
IX	Profit/(Loss) for the period from continuing operation (VII-VIII)	17.39	21.66	-41.49	124.14
X	Profit/(Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00
XI	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00
XII	Profit/(Loss) for the period for dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00
XIII	Profit/ (Loss) for the period (IX+XII)	17.39	21.66	-41.49	124.14
XIV	Other Comprehensive Income	0.00	0.00	0.00	0.00
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.63	0.63
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	-0.18	(0.18)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss				
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	17.39	21.66	(41.03)	124.59
XVI	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38
XVII	Reserves (Excluding Revaluation Reserve)				
XVIII	Earnings per equity shares (for continuing operation):				(390.50)
	(1) Basic (Rs)	0.11	0.13	(0.25)	0.76
	(2) Diluted (Rs)	0.11	0.13	(0.25)	0.76
XIX	Earnings Per Equity Share (for discontinued operation)				
	(1) Basic (Rs)	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00



XX	Earnings Per Equity Share (for continuing & discontinued operation)				
	(1) Basic (Rs)	0.11	0.13	(0.25)	0.76
	(2) Diluted (Rs)	0.11	0.13	(0.25)	0.76

1. The above results for the Quarter ended June 30, 2021 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 13-08-2021. The above results have been audited by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its

2. This financial results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

3. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

4. The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

- a. Pharma Division
- b. Chemicals Division

5. The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

6. The figures for the quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review.

7. Global disruption caused by CoVID-19 combined with a total nationwide lockdown has resulted in significant economic contraction in India. However, pharmaceuticals sector has seen relatively lesser disruption being part of essential items. Hence, all our manufacturing units were working and strictly following the guidelines issue by the Central and State Governments. Although, there are certain challenges which impacted the business being softer than normal such as Lack of availability of Raw Material, transportation of Raw Material and Finished Goods. Being a part of essential services sector, the Company continued their business & operations with the above constraints during the lockdown period.

8. Effective 1 April, 2019, the Company has adopted Ind AS 116- 'Leases' using modified retrospective approach. This has resulted in recognition of right of use assets equal to lease liabilities as on 1 April, 2019. The adoption of the standard did not have any material impact on the audited standalone financial results.


Date : 13.08.2021

Place INDORE

FOR-BIOFIL CHEMICALS & PHARMACEUTICALS LTD.



RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)




Segmentwise Revenue, Results and Capital Employed for quarter ended 30th June-2021

S.No.	Particulars	(Amount in Lakhs)			
		Quarter Ended			Year Ended
		June 30 , 2021	March 31, 2021	June 30 , 2020	March 31, 2021
		Un Audited	Audited	Un Audited	Audited
1	Segment Revenue				
	Pharma Division	468.05	1213.33	24.75	2,700.01
	Chemicals Division	68.82	210.54	205.35	875.03
	Other	2.06	0.03	63.62	80.45
	Gross Revenue	538.94	1,423.90	293.72	3,655.49
2	Segment Results				
	Pharma Division	27.43	14.55	(9.92)	117.25
	Chemicals Division	(2.89)	10.89	34.01	79.41
	Other	0.00	0.00	0.00	0.00
	Total Segment Profit Before Tax	24.54	25.44	24.09	196.66
	Interest Income	0.53	2.11	0.00	2.11
	Interest Expenses	0.97	0.82	2.44	6.42
	Other Unallocable Income net of Expenditure				
	Profit Before Tax	24.09	26.73	21.66	192.35
	Provision for current tax	6.70	32.75	0.00	32.75
	Item Related Earlier Year	0.00	35.01	0.00	35.01
	Profit After Tax	17.39	(41.03)	21.66	124.59
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	2,166.20	2158.34	2,125.11	2,158.34
	Chemicals Division	1,199.77	1165.50	1,228.95	1,165.50
	Other				
	Total (A)	3,365.98	3,323.84	3,354.06	3,323.84
	Segment Liabilities (B)				
	Pharma Division	1,618.39	1615.99	1,519.12	1,615.99
	Chemicals Division	110.41	94.77	254.79	94.77
	Other				
	Total (B)	1,728.80	1,710.76	1,773.91	1,710.76
4	Total Capital Employed (Segment Assets-Segment Liabilities)				
	Pharma Division	547.81	542.35	605.99	542.35
	Chemicals Division	1,089.37	1,070.73	974.16	1,070.73
	Other	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,637.18	1,613.09	1,580.15	1,613.09

DATE : 13/08/2021
PLACE: INDORE

FOR BIOFIL CHEMICALS & PHARMACEUTICAL


RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
DIN: 00028819



Limited Review Report
(Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements))

To
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore

We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the period ended 30th June 2021 being submitted by the Company pursuant to Regulation 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including relevant circular issued by the SEBI from time to time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Indian Accounting Standard 34, Interim Financial Reporting (Ind As 34) prescribed under section 133 of Companies Act 2013 and generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

Place: Indore
Date: 13.08.2021

For Maheshwari & Gupta
Chartered Accountants
FRN: 006179C

CA Sunil Maheshwari
Partner
M No.403346

UDIN: 21403346AAAAHW 2993